Samyang Holdings Corporation is a Korea-based holding company that specializes in the commercialization of first generics and drug delivery system (DDS)-based modified drugs for cancer treatment, alongside the development of small-molecule drugs, new biologic drugs, and cancer virus vaccines. The company exports its oncology products to over 25 countries, with its cytotoxic manufacturing facility authorized by regulatory authorities in Korea, Europe, and Japan. To enhance its Contract Development & Manufacturing capabilities, Samyang is constructing a new facility expected to achieve full cGMP operation.

Services include:
– Contract Development and Manufacturing (CDMO)
– Finished Dosage Forms
– Oncology Products
– Small-Molecule Drug Development
– New Biologic Drug Development
– Cancer Virus Vaccines

Samyang Corporation remains a significant player in the pharmaceutical industry, offering a range of services tailored to meet the needs of healthcare providers and patients. For more information, please visit samyang.com.